Prurigo nodularis: Pathogenesis and management.
Williams KA, Huang AH, Belzberg M, Kwatra SG.
J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.
Prurigo Nodularis: Review and Emerging Treatments.
Leis M, Fleming P, Lynde CW.
Skin Therapy Lett. 2021 May;26(3):5-8.
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Müller S, Zeidler C, Ständer S.
Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17.
Prurigo nodularis: Epidemiology and clinical features.
Huang AH, Williams KA, Kwatra SG.
J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators.
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
[Prurigo nodularis].
Misery L.
Rev Prat. 2020 Feb;70(2):187-189.
Prurigo Nodularis.
Kwatra SG.
JAMA Dermatol. 2022 Mar 1;158(3):336. doi: 10.1001/jamadermatol.2021.5307.
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.
Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, Yosipovitch G.
J Am Acad Dermatol. 2021 Mar;84(3):747-760. doi: 10.1016/j.jaad.2020.07.025. Epub 2020 Jul 15.
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA, Roh YS, Brown I, Sutaria N, Bakhshi P, Choi J, Gabriel S, Chavda R, Kwatra SG.
Expert Rev Clin Pharmacol. 2021 Jan;14(1):67-77. doi: 10.1080/17512433.2021.1852080. Epub 2020 Dec 11.
Prurigo Nodularis: Moving Forward.
Hanly A, Watsky KL.
Cutis. 2023 Dec;112(6):262-263. doi: 10.12788/cutis.0903.
